(Q42610826)

3 November 2017

title

Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain (English)

0 references

main subject

Clostridium botulinum

object named as

Clostridium botulinum

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0378-1119(03)00792-3

Corrigendum to “Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botolinum type A-Hall (Allergan) strain” [Gene 315 (2002) 21–32]

21 March 2024

corrigendum / erratum

1 reference

Li Zhang

1

1 reference

3 November 2017

Wei-Jen Lin

series ordinal

2

1 reference

3 November 2017

Shengwen Li

series ordinal

3

1 reference

3 November 2017

K. Roger Aoki

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14557061

21 March 2024

language of work or name

English

0 references

publication date

1 October 2003

1 reference

3 November 2017

2 October 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14557061

full work available at URL

21 March 2024

https://api.elsevier.com/content/article/PII:S0378111903007923?httpAccept=text/xml

1 reference

DOI

https://api.crossref.org/works/10.1016/S0378-1119(03)00792-3

https://api.elsevier.com/content/article/PII:S0378111903007923?httpAccept=text/plain

21 March 2024

1 reference

DOI

https://api.crossref.org/works/10.1016/S0378-1119(03)00792-3

21 March 2024

1 reference

3 November 2017

volume

315

1 reference

3 November 2017

page(s)

21-32

1 reference

Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle

3 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Pharmacology and immunology of botulinum toxin serotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Botulinum toxin type A (BOTOX) for treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Tyrosine phosphorylation modulates the activity of clostridial neurotoxins

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

The 26-mer peptide released from SNAP-25 cleavage by botulinum neurotoxin E inhibits vesicle docking

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

A peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cells

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Taxonomy of the Clostridia: Ribosomal Ribonucleic Acid Homologies among the Species

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Persistence of botulinum neurotoxin action in cultured spinal cord cells

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Crystal structure of botulinum neurotoxin type A and implications for toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Transposon Tn916 mutagenesis in Clostridium botulinum

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Botulinum neurotoxins: mechanism of action and therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Botulinum toxin: the story of its development for the treatment of human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Neurotoxins affecting neuroexocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Identification of the characteristics that underlie botulinum toxin potency: implications for designing novel drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

The complete amino acid sequence of the Clostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene

1 reference

https://api.crossref.org/works/10.1016%2FS0378-1119%2803%2900792-3

7 January 2021

Identifiers

DOI

1 reference

3 November 2017

1 reference